Logo Image

Authors

Surabhi Dangi-Garimella, PhD
Latest Article

Value-Based Agreements Take Center Stage at COA Summit

Pressure on regulators to reduce healthcare costs could be a response to the estimated $1 trillion in US expenditures from poor care coordination, administrative burdens, and fraud, said Jeff Mortier, partner at Farragut Partners, during the Community Oncology Alliance Payer Exchange Summit.

Surabhi Dangi-Garimella, PhD, AJMC Writer
Latest Article

Panelists Highlight Ways to Ease Transition to Value-Based Care

In a panel discussion this morning during the Association of Community Cancer Center (ACCC)’s 44th Annual Meeting & Cancer Center Business Summit, experts stressed the importance of integrating team-based care to break silos and allow a continued care transition as the move continues toward value-based care.

Susan F. Slovin, MD, PhD
Suzanne Morris, DVM
Latest Article

Progress in Prostate Cancer Care: Highlights From a Decade of Innovation

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.

Tara Petersen
Latest Article

Amorphous Treatment Paradigm in Melanoma Provides Countless Options

As new information regarding the efficacy of targeted and immunotherapeutic approaches emerge, the standard of care for patients with melanoma becomes slightly more altered.

Targeted Oncology Staff Writer
Latest Article

Tailoring Regimens for Different Age Groups With Multiple Myeloma

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series.

Targeted Therapies in Oncology Staff
Latest Article

Roundtable Discussion: Dietrich and Santos Look at Targeted Treatments for Patients With NSCLC

A 72-year-old White man presented with chest pain, cough, and dyspnea. He had a medical history of type 1 diabetes that was adequately controlled, and was a former smoker.

Targeted Therapies in Oncology Staff Writer
Latest Article

GRIFFIN Follow-Up Shows Promising Responses With Daratumumab plus VRD

Updated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.

TargetedOnc Staff Writer
Latest Article

FDA Considers New Warning and Label Recommendations for Breast Implants

According to a statement from the FDA, the agency has issued a draft guidance proposing labeling recommendations for breast implant manufacturers that would help patients understand the benefits and risks of implants. The labeling recommendations would include the addition of a boxed warning.

Terence M. Williams MD, PhD
Latest Article

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer

To determine the frequency and clinical characteristics of parotid gland metastasis from nasopharyngeal cancer and oropharyngeal cancer and define criteria for elective inclusion of parotidean nodes in the radiotherapy clinical target volume.

Teresa Benson, MA, LP
Latest Article

DNA Testing for Breast Cancer Risk: What the Current Medical Evidence Tells Us

While predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.

Terri W. McHugh, DO
Tewari
Thaer Khoury
Thao K . Huynh, PharmD , BCOP
Latest Article

Anti-TIGIT and ICI Combinations Supported by Early-Phase Research

Approaches that pair anti-TIGIT antibodies with other immune checkpoint inhibitors have sparked interest among investigators. Results of early-stage studies evaluating these unique combinations were recently presented at the American Association for Cancer Research Annual Meeting 2021. Later-stage studies are ongoing.

Thao Kim Huynh, PharmD
Latest Article

IDH Mutations Offer Hope as a Prognostic Indicator and Treatable Target in Gliomas

Several presentations at the 2019&nbsp;American Society of Clinical Oncology Annual Meeting highlighted a hopeful new direction in the treatment of gliomas, demonstrating the relevance of <em>IDH1/2</em> mutational status and its feasibility as a target of therapy.

This activity is supported by an educational grant from Eisai, Inc.
Thomas Krivak, MD
Tiffany M. Morgan, MD
Latest Article

Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer

The prognosis for patients with metastatic non&ndash;small cell lung cancer (NSCLC) is poor.&nbsp;However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing.

Tomas G. Lyons, MD
Latest Article

Immune Checkpoint Inhibition in Esophagogastric Cancers

The poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody and antagonists of the programmed death (PD)-1/PD-ligand 1 are essential immune checkpoint inhibitors that suppress T-cell activation.

Tony Berberabe
Latest Article

Microbiome Signatures Predict Melanoma Recurrence After Adjuvant ICI

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

Tony Berberabe, MPH

Tony Berberabe, MPH, is the assistant managing editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey. He covers genitourinary cancers and myeloproliferative neoplasms. Contact him at [email protected].

Latest Article

Evaluating Radium-223 Combinations and Bone Protection in mCRPC

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.

Tony Hagen
Latest Article

Genetic Testing is Essential in NSCLC Prior to Induction Therapy

Testing for driver mutations is essential before initiating therapy in patients with non&ndash;small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.

Tracey L. Evans, MD
Tracey Regan
Latest Article

Q & A With Kimberly L. Blackwell: The Treatment of HER2 Metastatic Breast Cancer

Since its approval in 1998 to treat metastatic disease, trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive breast cancer.

Usha Malhotra, MD
Latest Article

Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction Cancer

Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.

Vadim S. Koshkin, MD
Latest Article

Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been the standard of care in muscle-invasive bladder cancer for almost 2 decades. However, the rates of NAC utilization remain low and many patients are ineligible to receive cisplatin due to diminished renal function or other factors. Additionally, there are no reliable biomarkers routinely used in clinical practice that identify patients most likely to benefit from NAC, and limited prospective comparisons of the NAC regimens.

Vanessa Caceres
Latest Article

Immunotherapy’s Potential in Neuro-Oncology

A plenary session held November 15 at the Society of Neuro-Oncology’s (SNO) 2014 Annual Meeting in Miami Beach focused on immunotherapy’s promise as well as its challenges as a treatment for patients with brain cancer.

Veena Singh, MD
Latest Article

Clinical Validation and Utility of a Liquid Biopsy in NSCLC

Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.

Vinay Gupta, MD
Latest Article

Novel Proteasome Inhibitors for Multiple Myeloma

The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.